Pfizer framed as a defensive value anchor
Pfizer presents an attractive defensive value opportunity anchored by a robust balance sheet and a high dividend yield despite lagging price performance.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.